EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer



Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer



Urology 57(1): 127-132, January



Objectives: Several reports suggest an increased incidence of osteoporosis and concomitant fractures in men receiving androgen deprivation therapy (ADT) for prostate cancer. We sought to estimate the longitudinal effects of ADT on loss of bone density in this cross-sectional study. Methods: Hip and spine bone mineral density (BMD) studies were performed by dual-energy x-ray absorptiometry on 36 patients with prostate cancer. The year 0 cohort (n = 8) consisted of patients who had not yet begun planned ADT. These men were compared to patients receiving ADT who underwent BMD evaluation at year 2 (n = 6), year 4 (n = 7), year 6 (n = 5), year 8 (n = 5), and year 10 (n = 5) of therapy. All BMD values for the patients with prostate cancer were compared to age-matched control subjects. Results: Hip BMD was significantly lower in patients on ADT (mean BMD 0.802 g/cm2) compared with those not on ADT (mean BMD 0.935 g/cm2). Patients at year 0 had hip and spine BMD similar to age-matched control subjects. There was a significant trend for decreased hip BMD with increasing years of ADT (r = 0.46, P = 0.00008). This relationship was more dramatic when hip BMD at each time point was compared to age-matched control subjects (r = 0.55, P = 0.5 X 10-16). This bone loss was evident even up to year 10. BMD loss was more dramatic in patients who had undergone surgical castration than those receiving medical ADT (P = 0.08). Patients on intermittent ADT had similar BMD loss as patients on continuous ADT at year 2 and year 4 but demonstrated less bone loss at year 6 (P = 0.07) despite equivalently low testosterone levels. Conclusions: There is diminished BMD with increasing duration of ADT. Continuous ADT and surgical castration may be more deleterious than medical therapy, particularly when the medical therapy is given in an intermittent fashion.

(PDF emailed within 0-6 h: $19.90)

Accession: 011208339

Download citation: RISBibTeXText

PMID: 11164157

DOI: 10.1016/s0090-4295(00)00895-5



Related references

Progressive decrease in bone density over 10 years of androgen deprivation therapy in prostate cancer patients. Journal of Urology 163(4 Suppl ): 260, April, 2000

Decrease of bone mineral density in Japanese patients with non-metastatic prostate cancer treated with androgen deprivation therapy. Journal of Bone and Mineral Metabolism: -, 2018

Androgen deprivation therapy in patients with prostate cancer and changes in bone mineral density. Journal of Bone & Mineral Research 16(Suppl 1): S243, September, 2001

Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients. Asian Journal of Andrology 6(1): 75-77, 2004

Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy. Collegium Antropologicum 29(2): 589-591, 2006

Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocrine-Related Cancer 15(4): 943-952, 2008

Bone mineral density, pathological fractures and bisphosphonate therapy in prostate cancer patients on androgen deprivation therapy. Endocrine Regulations 45(4): 199-204, 2012

Effect of Androgen-deprivation Therapy on Bone Mineral Density in Japanese Patients with Prostate Cancer. In Vivo 32(2): 409-412, 2018

Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology 75(5): 1131-1137, 2010

Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab. Anticancer Research 37(7): 3667-3671, 2017

Bone mineral density in prostate cancer patients treated with androgen deprivation therapy; Preliminary results. European Urology Supplements 15(13): E1630-E1631, 2016

Evaluation of bone mass density on patients with prostate cancer prior to the start of androgen deprivation therapy. Bratislavske Lekarske Listy 110(9): 559-562, 2009

Self-reported exercise and bone mineral density in prostate cancer patients receiving androgen deprivation therapy. Journal of the American Association of Nurse Practitioners 26(1): 40-48, 2015

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. Journal of Urology 176(3): 972-8; Discussion 978, 2006

Peripheral or axial bone density measurements to identify osteoporosis in prostate cancer patients undergoing androgen deprivation therapy?. Urology 73(6): 1347-1351, 2009